Cypros Pharmaceutical Corp. appoints executive vice president and chief operating officer.CARLSBAD, Calif.--(BUSINESS WIRE)--May 13, 1996--Cypros Pharmaceutical Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CYPR) announced Monday the appointment of Stephen C. Eisold to the newly created position of executive vice president of corporate development and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . Eisold will be responsible for all development, marketing and operating functions of the company, with particular focus on growing the sales of Cypros's existing products, building critical mass with additional products and positioning the company's clinical development candidates as they move into Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the . Eisold brings 24 years of pharmaceutical industry experience to Cypros, all of which were in therapeutic areas relevant to the company's products. Most recently, Eisold was vice president and general manager at Gensia Inc. where he played a key role in building the sales infrastructure of that company. From 1973-1990, Eisold rose to the senior management level at Marion Laboratories where he was involved with the launch, marketing and sales of numerous pharmaceutical products including the cardiovascular drug Cardizem. Commenting on the new position, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Paul J. Marangos said, "Steve has presided over numerous pharmaceutical products in both large and small company settings and Cypros is now at the stage where the company can benefit from his experience. We are engaged in marketing and sales of two products, are actively seeking other products and are developing our own drugs through clinical trials. Steve will round out our senior management group and facilitate our becoming a profitable company." Cypros Pharmaceutical develops and markets acute-care, hospital-based products. The company's pre-clinical and clinical development programs focus on cytoprotective drugs designed to reduce ischemia (low blood flow) induced tissue damage in acute care settings. The company has three pre-clinical research and two clinical research programs. Six Phase II trials are currently in progress, which include four for CPC-111 (in angioplasty, coronary artery bypass grafting coronary artery bypass graft n. Abbr. CABG A surgical procedure in which a section of vein or other conduit is grafted between the aorta and a coronary artery below the region of an obstruction in that artery. surgery, congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. and sickle cell anemia sickle cell anemia n. A chronic, usually fatal inherited form of anemia marked by crescent-shaped red blood cells, occurring almost exclusively in Blacks, and characterized by fever, leg ulcers, jaundice, and episodic pain in the joints. crises), and two for CPC-211 (in stroke and head injury patients). The company also markets two intravenous agents (Insulin and Glofil) used to assess kidney function. CONTACT: Cypros Pharmaceutical Corp., Carlsbad David W. Nassif, 619/929-9500 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion